Media and supplements
Cellartis iPS Cell to Hepatocyte Differentiation System
Hepatocytes derived from human induced pluripotent stem (hiPS) cells using the Cellartis iPS Cell to Hepatocyte Differentiation System are an alternative to primary hepatocytes, as they exhibit sufficient expression levels of drug-metabolizing enzymes and transporters and demonstrate stable functionality over time in culture. In addition, hiPS cell-derived hepatocytes can provide an accurate reflection of the metabolic diversity observed in the human population.
Hepatocytes derived from human induced pluripotent stem (hiPS) cells using the Cellartis iPS Cell to Hepatocyte Differentiation System are an alternative to primary hepatocytes, as they exhibit sufficient expression levels of drug-metabolizing enzymes and transporters and demonstrate stable functionality over time in culture. In addition, hiPS cell-derived hepatocytes can provide an accurate reflection of the metabolic diversity observed in the human population. The Cellartis iPS Cell to Hepatocyte Differentiation System provides a complete solution for generating functional, hiPS cell-derived hepatocytes within three weeks.
The process of generating hiPS cell-derived hepatocytes begins with the directed differentiation of hiPS cells into Definitive Endoderm (DE) cells that are then differentiated further into hepatocytes. The complete system provides media and ready-to-use coatings for each step of the iPS-cell-to-hepatocyte differentiation protocol. Starting with approximately 3 x 106 undifferentiated hiPS cells, this system yields 5 x 106 hepatocytes, equivalent to a confluent monolayer of 50 cm2. This do-it-yourself system offers a solution for the consistent production of assay-ready cells from patient-derived cells or from Cellartis brand iPS cell lines—enabling highly reproducible results.
Hepatocytes obtained with the Cellartis iPS Cell to Hepatocyte Differentiation System express major hepatic markers and show relevant CYP enzyme activities based on the genetic background of the original hiPS cells from which they were derived. In addition, these freshly differentiated hepatocytes are functionally stable for a longer timeframe compared to cryopreserved primary hepatocytes, enabling prolonged experiments such as long-term toxicity assays or viral infection studies. Cellartis Hepatocyte Maintenance Medium (Cat. # Y30051) is recommended for long-term maintenance of hiPS cell-derived hepatocytes.
Highly reproducible, robust system—the exact same protocol has been shown to work across 25 different iPS cell lines, so there's no need to optimize for your lines
Ideal for drug metabolism and safety studies—consistently generate panels of >90% pure, functional, hiPS cell-derived hepatocytes with diverse genetic backgrounds
Customized starting materials—start with any disease-relevant iPS cell lines and create accurate liver disease models
Ready for personalized medicine—make patient-specific, disease-specific cells for therapeutic applications
Extended experimental window—hepatocytes can be used for a minimum of 11 days for functional tests
Cellartis DEF-CS 100 Culture System (Cat. # Y30020, not sold separately)
Cellartis Definitive Endoderm Differentiation Kit (Cat. # Y30030, not sold separately)
Cellartis Hepatocyte Differentiation Kit (Cat. # Y30050)
Asplund, A. et al. One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. Stem Cell Rev. Reports 12, 90–104 (2016).
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.